Skip to main content

Table 1 Therapeutic response to bDMARDs or small molecule therapy in individual joints by surgery type. Joints were subdivided as native joints, surgically replaced, or operated joint areas. Disease activity at baseline and at study termination (3–6 months) were tracked clinically (18 patients) and by ultrasound measures (16 patients). Power Doppler ultrasound (PDUS); grayscale ultrasound (GSUS)

From: Ultrasound detects synovitis in replaced and other surgically operated joints in rheumatoid arthritis patients

Native Joints
  BaselineEnd of Studyp-value
 N joints% Affected % Affected  
Tender (0–1)115635.726.0< 0.0001*
Swollen (0–1)112724.813.0< 0.0001*
% PDUS ≥146338.029.20.0002*
% GSUS ≥146362.057.00.045*
 N jointsMean (SD)Median (IQR)Mean (SD)Median (IQR) 
PDUS (0–3)4630.77 (1.11)0 (0–2)0.54 (0.94)0 (0–2)< 0.0001*
GSUS (0–3)4631.18 (1.10)1 (0–2)0.99 (1.01)1 (0–1)< 0.0001*
Replaced Joints
 N joints% Affected % Affected  
Tender (0–1)2528.032.00.56
Swollen (0–1)2254.645.50.41
% PDUS ≥12592.072.00.03*
% GSUS ≥12510080.00.03*
 N jointsMean (SD)Median (IQR)Mean (SD)Median (IQR) 
PDUS (0–3)252.28 (0.84)2 (2–3)1.56 (1.16)2 (0–2)0.007*
GSUS (0–3)252.28 (0.54)2 (2–3)1.72 (1.06)2 (1–2)0.01*
Operated Joint Areas
 N joints% Affected % Affected  
Tender (0–1)3641.744.40.74
Swollen (0–1)3636.138.90.80
% PDUS ≥12437.537.50.99
% GSUS ≥12445.837.50.32
 N jointsMean (SD)Median (IQR)Mean (SD)Median (IQR) 
PDUS (0–3)240.92 (1.28)0 (0–2)0.75 (1.11)0 (0–1)0.28
GSUS (0–3)241.04 (1.23)0 (0–2)0.71 (0.95)0 (0–2)0.12
  1. *McNemar’s test used for tender, swollen, PDUS≥1, and GSUS≥1 frequencies, Wilcoxon signed rank test used for PDUS (0–3) and GSUS (0–3)